These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 12571814)

  • 1. Pemetrexed in gastric cancer: clinical experience and future perspectives.
    Celio L; Buzzoni R; Longarini R; Marchianò A; Bajetta E
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):63-8. PubMed ID: 12571814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
    J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed: single-agent and combination phase I study overview.
    Boyer MJ; Rivory LP; Clarke SJ
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):18-23. PubMed ID: 12571806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trials of pemetrexed.
    Fossella FV; Gatzemeier U
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):8-16. PubMed ID: 12023787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.
    Socinski MA; Raju RN; Neubauer M; Smith DA; Richards DA; Savin M; Ruxer RL; Reynolds CH; Zhan F; Bromund JL; Chen R; Obasaju C
    J Thorac Oncol; 2008 Nov; 3(11):1308-16. PubMed ID: 18978567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis.
    Spielmann M; Martin M; Namer M; duBois A; Unger C; Dodwell DJ
    Clin Breast Cancer; 2001 Apr; 2(1):47-51. PubMed ID: 11899382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed in advanced colorectal cancer.
    Louvet C; de Gramont A
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):56-62. PubMed ID: 15655939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ; Eisenhauer E; Butts C; Gregg R; Dancey J; Fisher B; Iglesias J
    J Clin Oncol; 1999 Apr; 17(4):1194. PubMed ID: 10561178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.
    Manegold C
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):32-6. PubMed ID: 12917819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
    Jones RJ; Twelves CJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of pemetrexed in the treatment of colorectal cancer.
    Hochster H
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):54-6. PubMed ID: 12571812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed in bladder, head and neck, and cervical cancers.
    Paz-Ares L; Ciruelos E; García-Carbonero R; Castellano D; Lopez-Martín A; Cortés-Funes H
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):69-75. PubMed ID: 12571815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer.
    Bajetta E; Celio L; Buzzoni R; Ferrari L; Marchianò A; Martinetti A; Longarini R; Becerra C; Ilardi C; John W
    Ann Oncol; 2003 Oct; 14(10):1543-8. PubMed ID: 14504056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed, an novel multitargeted antifolate: current development and future directions. Proceedings of a meeting. August 17-19, 2000. Colorado Springs, Colorado, USA.
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):1-61; quiz 62-9. PubMed ID: 12023785
    [No Abstract]   [Full Text] [Related]  

  • 16. Pemetrexed in pancreatic cancer.
    Kindler HL
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):49-53. PubMed ID: 12571811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of phase I trials of multitargeted antifolate (MTA, LY231514).
    Rinaldi DA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):82-8. PubMed ID: 10598560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study.
    Jalal S; Ansari R; Govindan R; Bhatia S; Bruetman D; Fisher W; Masters G; White A; Stover D; Yu M; Hanna N;
    J Thorac Oncol; 2009 Jan; 4(1):93-6. PubMed ID: 19096313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.
    Hanauske AR; Chen V; Paoletti P; Niyikiza C
    Oncologist; 2001; 6(4):363-73. PubMed ID: 11524555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study.
    Zhang DS; Jin Y; Luo HY; Wang ZQ; Qiu MZ; Wang FH; Li YH; Xu RH
    Br J Cancer; 2015 Jan; 112(2):266-70. PubMed ID: 25474247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.